TRAX FIRST TRACKS BIOTHERAPEUTICS revenue, earnings and financials
For the quarter ended June 30, 2026, FIRST TRACKS BIOTHERAPEUTICS reported revenue of n/a, net income of −$33.4M and diluted EPS of −$0.95; for the fiscal year ended December 2025 revenue was n/a.
TRAX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$179M, net income −$166M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$181M, net income −$164M (margin n/a), EPS n/a
TRAX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$33.4M, EPS −$0.95
- Quarter ended Mar 31, 2026: revenue n/a, net income −$50.5M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$42.4M, EPS −$1.47
- Quarter ended Mar 31, 2025: revenue n/a, net income −$47.2M, EPS n/a
TRAX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$143M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$126M, share buybacks n/a
TRAX balance sheet
- Jun 30, 2026: cash $168M, total assets $183M, total liabilities n/a, shareholders' equity $169M
- Mar 31, 2026: cash $248M, total assets $291M, total liabilities n/a, shareholders' equity $257M
- Dec 31, 2025: cash $238M, total assets $331M, total liabilities n/a, shareholders' equity $287M
Is TRAX profitable?
No. FIRST TRACKS BIOTHERAPEUTICS lost $166M in its latest fiscal year.